Our approach to patient safety

Our pharmacovigilance and patient safety teams identify potential safety issues and mitigate their impact on patients in order to improve the patient experience.

Over the course of 2022, at any given time, these teams were supporting approximately 250 clinical trials and approximately 200 marketed products and devices.

These teams also address any risks of our medicines being counterfeited or diverted by regularly providing education and training to employees, health care providers and law enforcement officials in higher-risk geographies.

Our approach to quality

We have robust systems in place to ensure the products we manufacture are high quality and available when customers and patients need them. Our Quality Council oversees our quality strategy and is accountable directly to our CEO. Expert teams oversee every aspect of our processes, from discovery and development through manufacturing and delivery.

In addition to internal control measures, our quality processes are reviewed, certified and audited by multiple external regulatory authorities and notified parties and we use an integrated enterprise quality management system that complies with all applicable global standards and regulations.  

Assurance of supply

Our assurance of supply programme is designed to help us maintain supply of medicines and products. We ensure patients and customers continue to receive uninterrupted supply of the products they need, even in unpredictable circumstances, by identifying and qualifying backup suppliers, scanning the environment for potential risks and doing scenario planning.

To ensure the quality and integrity of our supply chain, we have a supply chain management system that includes criticality assessment, controls, relationship management and continuous monitoring.

AbbVie's supply chain is consistently ranked as a global supply chain leader, and in 2022, was ranked #20 in the Gartner Supply Chain Top 25.